Tempest Therapeutics, Inc.
TPST
$1.92
-$0.02-1.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.10% | -0.71% | 3.77% | 6.73% | 16.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.76% | 2.23% | 36.98% | 52.24% | 44.13% |
| Operating Income | 36.76% | -2.23% | -36.98% | -52.24% | -44.13% |
| Income Before Tax | 37.24% | -1.51% | -35.75% | -50.54% | -41.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.24% | -1.51% | -35.75% | -50.54% | -41.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.24% | -1.51% | -35.75% | -50.54% | -41.88% |
| EBIT | 36.76% | -2.23% | -36.98% | -52.24% | -44.13% |
| EBITDA | 36.81% | -2.76% | -37.91% | -52.77% | -44.69% |
| EPS Basic | 65.53% | 49.15% | 30.19% | 19.59% | 22.03% |
| Normalized Basic EPS | 65.53% | 49.15% | 30.19% | 19.59% | 22.03% |
| EPS Diluted | 65.53% | 49.15% | 30.19% | 19.59% | 22.03% |
| Normalized Diluted EPS | 65.53% | 49.15% | 30.19% | 19.59% | 22.03% |
| Average Basic Shares Outstanding | 93.26% | 114.09% | 105.29% | 91.63% | 81.50% |
| Average Diluted Shares Outstanding | 93.26% | 114.09% | 105.29% | 91.63% | 81.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |